Liens utiles

Institut National du Cancer agence d'expertise sanitaire et scientifique en cancérologie

Nota Bene Cancer bulletin de veille bibliographique dans les divers domaines de la recherche sur les cancers

Onco Actu brèves sur le web anglophone

 

Tous les liens utiles

Accueil » La R&D d'Unicancer » Les publications de la R&D d'Unicancer » Les publications

Publications de la R&D d'Unicancer

2015

Impact of centralization on aCGH-based genomic profiles for precision medicine in oncology.

Commo F et al., Ann Oncol. 2015 Mar;26(3):582-8. doi: 10.1093/annonc/mdu582. Epub 2014 Dec 23.

2015

Applying the Longitudinal Model from Item Response Theory to Assess the Health-Related Quality of Life in the PRODIGE 4/ACCORD 11 Randomized Trial.

Barbieri A et al., Med Decis Making. 2015 Dec 18. pii: 0272989X15621883

2015

Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial.

Gérard JP, et al., Radiother Oncol. 2015 May;115(2):246-52. doi: 10.1016/j.radonc.2015.04.003. Epub 2015 Apr 24.

2015

Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial.

Levy A, et al., Radiother Oncol. 2015 Mar;114(3):415-6. doi: 10.1016/j.radonc.2015.02.008. Epub 2015 Mar 11

2015

Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial.

Van den Berg H, et al. Eur J Cancer. 2015 Nov;51(16):2453-64. doi: 10.1016/j.ejca.2015.06.123. Epub 2015 Aug 10

2015

Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.

Gravis G et al., Eur Urol. 2015 Aug;68(2):196-204. doi: 10.1016/j.eururo.2014.09.022. Epub 2014 Sep 30

2015

Definition of lymph node areas for radiotherapy of prostate cancer: A critical literature review by the French Genito-Urinary Group and the French Association of Urology (GETUG-AFU).

Sargos P et al., Cancer Treat Rev. 2015 Dec;41(10):814-20. doi: 10.1016/j.ctrv.2015.10.005. Epub 2015 Oct 23

2015

First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG).

Ravaud A et al.; Ann Oncol. 2015 Jun;26(6):1123-8. doi: 10.1093/annonc/mdv149. Epub 2015 Mar 23.

2013

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

Gravis G et al., Lancet Oncol. 2013 Feb;14(2):149-58. doi: 10.1016/S1470-2045(12)70560-0. Epub 2013 Jan 8.

2015

Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial.

Blanchard P, et al., Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):85-92. doi: 10.1016/j.ijrobp.2015.09.020. Epub 2015 Sep 25.